Evidence map›Paper›PMID 34177436›Full record

ArticleMolecular syndromology2021

Neuroimaging Findings in Patients with

Mar Jiménez de la Peña, Ana Jiménez de Domingo, Pilar Tirado, Beatriz Calleja-Pérez, Luis A Alcaraz, Sara Álvarez, Jonathan Williams, James R Hagman, Andrea H Németh, Alberto Fernández-Jaén

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in Molecular syndromology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Dystrophin genetic variants and autism.Discover mental health · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 3 countries.

Mar Jiménez de la PeñaNeuroimaging, Hospital Universitario Quirónsalud, Madrid, Spain.
Ana Jiménez de DomingoDepartment of Pediatric Neurology, Hospital Universitario Quirónsalud, Madrid, Spain.
Pilar TiradoDepartment of Pediatric Neurology, Hospital Universitario La Paz, Madrid, Spain.
Beatriz Calleja-PérezPediatric Primary Care, C.S. Doctor Cirajas, Madrid, Spain.
Luis A AlcarazBioarray, Diagnóstico Genético, Alicante, Spain.
Sara ÁlvarezGenomics and Medicine, NIMGenetics, Madrid, Spain.
Jonathan WilliamsOxford Medical Genetics Laboratories, Churchill Hospital, Oxford, United Kingdom.
James R HagmanDepartment of Immunology and Genomic Medicine, National Jewish Health, Denver, Colorado, USA.
Andrea H NémethNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.
Alberto Fernández-JaénDepartment of Pediatric Neurology, Hospital Universitario Quirónsalud, and Medicine School, Universidad Europea de Madrid, Madrid, Spain.
Hospital Universitario Quirónsalud Madrid · ESChurchill Hospital · GBHospital Universitario La Paz · ESMadrid Health Service · ESNational Jewish Health · USOxford University Hospitals NHS Trust · GBUniversidad Europea de Madrid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early B cell factor 3 (EBF3) is a transcription factor involved in brain development. Heterozygous, loss-of-function mutations in

Indexed as

ADHDAutismEBF3NeuroimagingTractography

Identifiers

PMID34177436
PMCPMC8215950
OpenAlexW3156993074

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.